Erin M Rock1, Cheryl L Limebeer2, Linda A Parker2. 1. Department of Psychology and Collaborative Neuroscience Program, University of Guelph, Guelph, ON, N1G 2W1, Canada. erock@uoguelph.ca. 2. Department of Psychology and Collaborative Neuroscience Program, University of Guelph, Guelph, ON, N1G 2W1, Canada.
Abstract
RATIONALE: Δ(9)-Tetrahydrocannabinol (THC) and cannabidiolic acid (CBDA) found in cannabis both reduce the distressing symptom of nausea, but their combined effects are not understood. OBJECTIVE: The potential of combined doses of THC and CBDA to reduce acute nausea and anticipatory nausea in rodent models was assessed. MATERIALS AND METHODS: For acute nausea, the potential of cannabinoid pretreatment(s) to reduce LiCl-induced nausea paired with saccharin was evaluated in a subsequent drug free taste reactivity test, followed by a taste avoidance test. For anticipatory nausea, the potential of the cannabinoid pretreatment(s) to reduce the expression of LiCl-induced contextually elicited conditioned gaping was evaluated. RESULTS: Combined subthreshold doses of THC (0.01 and 0.1 mg/kg) and CBDA (0.01 and 0.1 μg/kg) reduced acute nausea. Higher doses of THC (1.0, 10 mg/kg) or CBDA (1.0, 10 μg/kg) alone, as well as these combined doses also reduced acute nausea. THC (10 mg/kg) interfered with conditioned taste avoidance, an effect attenuated by CBDA (10 μg/kg). On the other hand, combined subthreshold doses of THC (0.01 and 0.1 mg/kg) and CBDA (0.01 and 0.1 μg/kg) did not suppress contextually elicited conditioned gaping in a test for anticipatory nausea. However, higher doses of THC (1.0, 10 mg/kg) or CBDA (1.0, 10 μg/kg) alone, as well as these combined doses, also reduced anticipatory nausea. Only at the highest dose (10 mg/kg) did THC impair locomotor activity, but CBDA did not at any dose. CONCLUSIONS: Combined subthreshold doses of THC:CBDA are particularly effective as a treatment for acute nausea. At higher doses, CBDA may attenuate THC-induced interference with learning.
RATIONALE: Δ(9)-Tetrahydrocannabinol (THC) and cannabidiolic acid (CBDA) found in cannabis both reduce the distressing symptom of nausea, but their combined effects are not understood. OBJECTIVE: The potential of combined doses of THC and CBDA to reduce acute nausea and anticipatory nausea in rodent models was assessed. MATERIALS AND METHODS: For acute nausea, the potential of cannabinoid pretreatment(s) to reduce LiCl-induced nausea paired with saccharin was evaluated in a subsequent drug free taste reactivity test, followed by a taste avoidance test. For anticipatory nausea, the potential of the cannabinoid pretreatment(s) to reduce the expression of LiCl-induced contextually elicited conditioned gaping was evaluated. RESULTS: Combined subthreshold doses of THC (0.01 and 0.1 mg/kg) and CBDA (0.01 and 0.1 μg/kg) reduced acute nausea. Higher doses of THC (1.0, 10 mg/kg) or CBDA (1.0, 10 μg/kg) alone, as well as these combined doses also reduced acute nausea. THC (10 mg/kg) interfered with conditioned taste avoidance, an effect attenuated by CBDA (10 μg/kg). On the other hand, combined subthreshold doses of THC (0.01 and 0.1 mg/kg) and CBDA (0.01 and 0.1 μg/kg) did not suppress contextually elicited conditioned gaping in a test for anticipatory nausea. However, higher doses of THC (1.0, 10 mg/kg) or CBDA (1.0, 10 μg/kg) alone, as well as these combined doses, also reduced anticipatory nausea. Only at the highest dose (10 mg/kg) did THC impair locomotor activity, but CBDA did not at any dose. CONCLUSIONS: Combined subthreshold doses of THC:CBDA are particularly effective as a treatment for acute nausea. At higher doses, CBDA may attenuate THC-induced interference with learning.
Authors: S A Varvel; J L Wiley; R Yang; D T Bridgen; K Long; A H Lichtman; B R Martin Journal: Psychopharmacology (Berl) Date: 2006-03-30 Impact factor: 4.530
Authors: E M Rock; D Bolognini; C L Limebeer; M G Cascio; S Anavi-Goffer; P J Fletcher; R Mechoulam; R G Pertwee; L A Parker Journal: Br J Pharmacol Date: 2012-04 Impact factor: 8.739
Authors: Chandni Hindocha; Tom P Freeman; Grainne Schafer; Chelsea Gardener; Ravi K Das; Celia J A Morgan; H Valerie Curran Journal: Eur Neuropsychopharmacol Date: 2014-12-05 Impact factor: 4.600
Authors: Erin M Rock; Cheryl L Limebeer; Gavin N Petrie; Lauren A Williams; Raphael Mechoulam; Linda A Parker Journal: Psychopharmacology (Berl) Date: 2017-04-20 Impact factor: 4.530
Authors: Andrea Bollom; Jasmine Austrie; William Hirsch; Judy Nee; Daniel Friedlander; Johanna Iturrino; Sarah Ballou; Anthony Lembo Journal: J Clin Gastroenterol Date: 2018-10 Impact factor: 3.062
Authors: Roger G Pertwee; Erin M Rock; Kelsey Guenther; Cheryl L Limebeer; Lesley A Stevenson; Christeene Haj; Reem Smoum; Linda A Parker; Raphael Mechoulam Journal: Br J Pharmacol Date: 2017-12-05 Impact factor: 8.739
Authors: Erin M Rock; Megan T Sullivan; Sarah Pravato; Mick Pratt; Cheryl L Limebeer; Linda A Parker Journal: Psychopharmacology (Berl) Date: 2020-01-02 Impact factor: 4.530
Authors: Lyndsey L Anderson; Maia G Etchart; Dilara Bahceci; Taliesin A Golembiewski; Jonathon C Arnold Journal: Sci Rep Date: 2021-07-22 Impact factor: 4.379